RT Journal Article
SR Electronic
T1 Preoperative Serum Vascular Endothelial Growth Factor-C (VEGF-C) Levels Predict Recurrence in Patients with Esophageal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 165
OP 169
VO 28
IS 1A
A1 KIMURA, HITOSHI
A1 KATO, HIROYUKI
A1 TANAKA, NARITAKA
A1 INOSE, TAKANORI
A1 FARIED, AHMAD
A1 SOHDA, MAKOTO
A1 NAKAJIMA, MASANOBU
A1 FUKAI, YASUYUKI
A1 MIYAZAKI, TATSUYA
A1 MASUDA, NORIHIRO
A1 MANDA, RYOKUHEI
A1 FUKUCHI, MINORU
A1 OJIMA, HITOSHI
A1 TSUKADA, KATSUHIKO
A1 KUWANO, HIROYUKI
YR 2008
UL http://ar.iiarjournals.org/content/28/1A/165.abstract
AB Background: Circulating vascular endothelial growth factor-C (VEGF-C) levels were measured in patients with esophageal cancer to assess the value of VEGF-C as a biomarker for predicting tumor recurrence. Patients and Methods: Preoperative serum samples were acquired from 80 patients and healthy volunteers who served as normal controls. VEGF-C levels were assessed using enzyme-linked immunosorbent assay (ELISA). Results: The preoperative serum VEGF-C level in patients with esophageal cancer was significantly higher than in healthy volunteers. Furthermore, patients with recurrence had significantly higher preoperative serum VEGF-C levels than patients without recurrence, and a high preoperative serum VEGF-C level was found to be an independent risk factor for recurrence, in addition to lymph node metastasis. Conclusion: Preoperative VEGF-C levels may reflect malignancy, such as lymph node metastasis, and predict recurrence in patients with esophageal cancer. Therefore, the preoperative VEGF-C level may be a useful biomarker for choice of multimodality therapy.